


(51) International Patent Classification:
C07D 201/00 (2006.01)(21) International Application Number:
PCT/EP2024/080350(22) International Filing Date:
25 October 2024 (25.10.2024)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
23206564.9 27 October 2023 (27.10.2023) EP
24167036.3 27 March 2024 (27.03.2024) EP
24206215.6 11 October 2024 (11.10.2024) EP(71) Applicant: PHILOCHEM AG [CH/CH]; Libernstrasse 3,
8112 Otelfingen (CH).(72) Inventors: CAZZAMALLI, Samuele; c/o Philochem
AG, Libernstrasse 3, 8112 Otelfingen (CH). GEORGIEV,
Tony; c/o Philochem AG, Libernstrasse 3, 8112 Otelfin-
gen (CH). OEHLER, Sebastian; c/o Philochem AG,Libernstrasse 3, 8112 Otelfingen (CH). MIGLIORINI,
Francesca; c/o Philochem AG, Libernstrasse 3, 8112
Otelfingen (CH). NERI, Dario; c/o Philochem AG, Libern-
strasse 3, 8112 Otelfingen (CH). PARK KIM, Young Seo;
c/o Philochem AG, Libernstrasse 3, 8112 Otelfingen (CH).(74) Agent: HOFFMANN EITLE PATENT- UND
RECHTSANWÄLTE PARTMBB, ASSOCIATION NO.
151; Arabellastraße 30, 81925 Munich (DE).(81) Designated States (unless otherwise indicated, for every
kind of national protection available): AE, AG, AL, AM,
AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ,
CA, CH, CL, CN, CO, CR, CU, CV, CZ, DE, DJ, DK, DM,
DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT,
HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE, KG,
KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY,
MA, MD, MG, MK, MN, MU, MW, MX, MY, MZ, NA,
NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO,
RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH,
TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS,
ZA, ZM, ZW.

(54) Title: ACID PHOSPHATASE 3 LIGANDS FOR TARGETED DELIVERY APPLICATIONS



(57) Abstract: The present invention relates to ligands against Acid Phosphatase 3 (ACP3 or ACP3), also known as Prostatic Acid Phosphatase (PAP). Selective ACP3 ligands may be able to exclusively interact with antigens expressed on the surface of tumor cells for in vivo pharmaco-delivery applications. The ligand may display very high affinity and selectivity towards ACP3 to enable targeted delivery of a payload, including therapeutic and diagnostic payloads, to a site afflicted by or at risk of a disease characterized by the expression of ACP3.

[Continued on next page]

(84) Designated States (*unless otherwise indicated, for every kind of regional protection available*): ARIPO (BW, CV, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SC, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, ME, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:

- *as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii))*
- *of inventorship (Rule 4.17(iv))*

Published:

- *without international search report and to be republished upon receipt of that report (Rule 48.2(g))*
- *with sequence listing part of description (Rule 5.2(a))*